Certara Enters Definitive Agreement for the Sale of its Regulatory and Medical Writing Business to Veristat
Certara agreed to sell its Regulatory and Medical Writing business to Veristat for total consideration of up to $135 million. The divested unit generated $50 million in revenue and $17 million in adjusted EBITDA during 2025 and employs approximately 220 people.
Key figures
- Deal Value Usd
- 135000000
- Segment revenue 2025
- 50000000
- Segment adj ebitda 2025
- 17000000
- Employees in divested unit
- 220
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.